WHO ICTRP trial
A 26-week, randomized, double blind, parallel-group multicenter study to assess…
NL-OMON43821 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON43821 |
|---|---|
| Public title | A 26-week, randomized, double blind, parallel-group multicenter study to assess the efficacy and safety of QVA149 (110/50 mcg o.d.) vs tiotropium (18 mcg o.d.) + salmeterol/fluticasone propionate FDC (50/500 mcg b.i.d.) in patients with moderate to severe COPD |
| Scientific title | A 26-week, randomized, double blind, parallel-group multicenter study to assess the efficacy and safety of QVA149 (110/50 mcg o.d.) vs tiotropium (18 mcg o.d.) + salmeterol/fluticasone propionate FDC (50/500 mcg b.i.d.) in patients with moderate to severe COPD - NOV741 |
| Primary sponsor | TFS Trial Form Support BV |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 4 |
| Countries | The Netherlands |
| Conditions | airflow limitation COPD;10024970;airflow limitation;COPD |
| Interventions | QVA149 110/50 *g capsules o.d. for inhalation, supplied in blisters delivered via Novartis single dose dry powder inhaler Novartis single dose dry powder inhalerNovartis single dose dry powder inhaler. Salmeterol/fluticasone propionate FDC… |
| Registration date | Jun 27, 2016 |
| Target size | 95 |
| Secondary IDs | 2015 000114 22;NL54207.100.15 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: